SAID IBRAHIMI: Open Payments
NPI 1740560861 · DANVILLE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$23,738 in 292 payments from 19 companies in 2025. Trend: 2023 $5,803 · 2024 $6,153 · 2025 $23,738
Honoraria: $14,600Food & beverage: $7,069Travel & lodging: $2,042Education: $27
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 35 | $17,663 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 35 | $753 |
| Alkermes, Inc. | 20 | $643 |
| SK Life Science, Inc. | 36 | $631 |
| ABBVIE INC. | 23 | $565 |
| E.R. Squibb & Sons, L.L.C. | 17 | $470 |
| Otsuka America Pharmaceutical, Inc. | 15 | $428 |
| Janssen Pharmaceuticals, Inc | 6 | $324 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $312 |
| Vanda Pharmaceuticals Inc. | 8 | $310 |
Products named: Qelbree, CAPLYTA, REXULTI, COBENFY, ARISTADA, VRAYLAR, TRINTELLIX, FANAPT.
Industry payments across CA — which companies pay providers there.
